Key features and details
- Mouse monoclonal [TB21] to TGF beta 1
- Suitable for: IHC-Fr, IHC-P, ELISA, ICC/IF, Neutralising, WB
- Reacts with: Sheep, Human, Pig
- Isotype: IgG1
Product nameAnti-TGF beta 1 antibody [TB21]
See all TGF beta 1 primary antibodies
DescriptionMouse monoclonal [TB21] to TGF beta 1
SpecificityThis antibody recognises natural and recombinant TGF beta 1. It reacts with both dimeric and monomeric natural forms under reducing and non reducing conditions. Full length, inactive 44 kD TGFB1 is cleaved into mature TGFB1 (13 kD). TGFB1 also homodimerizes and heterodimerizes with TGFB2, so there is potential for multiple different band sizes in WB.
Tested applicationsSuitable for: IHC-Fr, IHC-P, ELISA, ICC/IF, Neutralising, WBmore details
Species reactivityReacts with: Sheep, Human, Pig
Predicted to work with: Rat
Human TGF Beta 1 from human platelets.
- Purchase matching WB positive control:Recombinant human TGF beta 1 protein (Active)
- Human breast carcinoma.
We have mixed feedback from customers about the Rat specificity so the Rat species has been moved to predicted as we can't guarantee it. The antibody has been successfully used with Rat samples in publication PMID 22471627 and PMID 19820199 though.
This clone (TB21) demonstrates neutralising activity against TGF beta 1 in cell proliferation assays. Removal of sodium azide is recommended prior to use in functional assays.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term.
Storage bufferPreservative: 0.09% Sodium azide
Concentration information loading...
PurityImmunogen affinity purified
Primary antibody notesThis clone (TB21) demonstrates neutralising activity against TGF beta 1 in cell proliferation assays. Removal of sodium azide is recommended prior to use in functional assays.
Light chain typekappa
Our Abpromise guarantee covers the use of ab27969 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IHC-Fr||Use at an assay dependent concentration.|
|IHC-P||Use at an assay dependent concentration.|
|ELISA||Use at an assay dependent concentration.|
|ICC/IF||Use at an assay dependent concentration.|
|Neutralising||Use at an assay dependent concentration. PubMed: 8237223|
See Abreview. We recommend using BSA in blocking solution. Full length, inactive 44 kD TGFB1 is cleaved into mature TGFB1 (13 kD). TGFB1 also homodimerizes and heterodimerizes with TGFB2, so there is potential for multiple different band sizes in WB.
FunctionMultifunctional protein that controls proliferation, differentiation and other functions in many cell types. Many cells synthesize TGFB1 and have specific receptors for it. It positively and negatively regulates many other growth factors. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts.
Tissue specificityHighly expressed in bone. Abundantly expressed in articular cartilage and chondrocytes and is increased in osteoarthritis (OA). Co-localizes with ASPN in chondrocytes within OA lesions of articular cartilage.
Involvement in diseaseDefects in TGFB1 are the cause of Camurati-Engelmann disease (CE) [MIM:131300]; also known as progressive diaphyseal dysplasia 1 (DPD1). CE is an autosomal dominant disorder characterized by hyperostosis and sclerosis of the diaphyses of long bones. The disease typically presents in early childhood with pain, muscular weakness and waddling gait, and in some cases other features such as exophthalmos, facial paralysis, hearing difficulties and loss of vision.
Sequence similaritiesBelongs to the TGF-beta family.
The precursor is cleaved into mature TGF-beta-1 and LAP, which remains non-covalently linked to mature TGF-beta-1 rendering it inactive.
Cellular localizationSecreted > extracellular space > extracellular matrix.
- Information by UniProt
- Cartilage-inducing factor antibody
- CED antibody
- Differentiation inhibiting factor antibody
ab27969 staining TGF beta 1 in rat kidney tissue sections by Immunohistochemistry (frozen sections). Tissue was fixed with acetone and then blocked with 2% BSA for 2 hours at 25°C followed by incubation with the primary antibody, at a 1/200 dilution, for 9 hours at 4°C. The secondary antibody used was a goat anti-mouse IgG conjugated to Alexa Fluor® 594 (red) used at a 1/500 dilution.
ab 27969 staining TGF beta 1 in human 293ft cells by Immunocytochemistry/ Immunofluorescence.
The 293 FT cells were cultured for 3 days then fixed with 3.7% formaldehyde for 10 minutes and blocked with 5% BSA in PBS for 1 hour at +4°C. The cells were incubated with the primary antibody at 1/200 dilution overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 555 Goat anti-Rabbit IgG used at a dilution of 1/200.
ab27969 staining TGF beta 1 in Human ureter tissue sections by Immunohistochemistry (IHC-Fr - frozen sections). Tissue was fixed with paraformaldehyde and blocked with 1% serum for 30 minutes at 20°C. Samples were incubated with primary antibody (1/150) for 16 hours at 4°C. A Cy2®-conjugated Goat anti-mouse polyclonal (1/200) was used as the secondary antibody.
ab27969 has been referenced in 48 publications.
- Gu TT et al. Pterostilbene alleviates fructose-induced renal fibrosis by suppressing TGF-ß1/TGF-ß type I receptor/Smads signaling in proximal tubular epithelial cells. Eur J Pharmacol 842:70-78 (2019). PubMed: 30336139
- Wang N et al. Carcinoembryonic antigen cell adhesion molecule 1 inhibits the antitumor effect of neutrophils in tongue squamous cell carcinoma. Cancer Sci 110:519-529 (2019). PubMed: 30565803
- Cen S et al. Autophagy enhances mesenchymal stem cell-mediated CD4+ T cell migration and differentiation through CXCL8 and TGF-ß1. Stem Cell Res Ther 10:265 (2019). PubMed: 31443687
- Hasan H et al. Thrombin Induces Angiotensin II-Mediated Senescence in Atrial Endothelial Cells: Impact on Pro-Remodeling Patterns. J Clin Med 8:N/A (2019). PubMed: 31581517
- Song S et al. Blocking transforming growth factor-beta reduces the migration and invasion of the residual tumour after TAE. Am J Transl Res 11:2155-2167 (2019). PubMed: 31105825